peptide acylation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
As a mod for Half-Life, Half-Life: Echoes is a first-person shooter that differs slightly from the base game. The first part of the game is mainly survival horror, limiting the player's arsenal and introducing monsters, including unused enemies. The second half of the game has the player fight against the HECU Marines.
Feminizing hormone therapy, also known as transfeminine hormone therapy, is a form of gender-affirming hormone therapy (GAHT) which change the primary and secondary sex characteristics of transgender people from masculine to feminine. It is one of the two common type of GAHT the other being masculinizing hormone therapy) and is used to treat transgender women and non-binary transfeminine individuals. Some others, in particular intersex people, but also some non-transgender people, take this form of therapy according to their personal needs and preferences. The purpose of the therapy is to cause the development of the secondary sex characteristics of the desired sex, such as breasts and a feminine pattern of hair, fat, and muscle distribution. It cannot undo many of the changes produced by naturally occurring puberty, which may necessitate surgery and other treatments to reverse (see below). The medications used for feminizing hormone therapy include estrogens, antiandrogens, progestogens, and gonadotropin-releasing hormone modulators (GnRH modulators). Feminizing hormone therapy has been empirically shown to reduce the distress and discomfort associated with gender dysphoria in transfeminine individuals.
== Chemical properties == Trisulfuryl fluoride is a reactive compound. It is known to decompose into disulfuryl fluoride when heated. The compound reacts with certain compounds, like the sodium cyanohydrin salt, to form other fluorosulfates. It slowly hydrolizes in the solution of potassium hydroxide (KOH):
Sources: en.wikipedia.org
== Aggregate processes == While the underlying process of radioactive decay is subatomic, historically and in most practical cases it is encountered in bulk materials with very large numbers of atoms. This section discusses models that connect events at the atomic level to observations in aggregate.
== External links == "Gonadotrophin-Releasing Hormone Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-04. GNRHR+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== Remembrance === The Greater Poland uprising was not remembered as well as the January Uprising or the Warsaw Uprising in Polish history and popular culture, despite it being the only one of the three uprisings cited that succeeded. This was due to three factors, the first due to it being an uprising that did not apply to Polish tradition. There were no major icons of the uprising, no heroes, no real martyrs. The uprising could not be passed down by generations as a heroic fight to the death, since it was just a military operation that pushed the Germans out of a section of the Prussian Partition. Secondly, the fighters of the uprising were not engaged for the whole uprising and many of them did not find themselves part of any actual fighting group. Many part of the original uprisings simply took up arms, liberated their towns and by sundown they had eaten dinner and went back to civilian life. Thirdly, there were very few casualties. On 23 December 2021, Polish President Andrzej Duda declared 27 December as a National Holiday, commemorating this uprising.
=== Skeletal muscle === In 1998, skeletal muscle was identified as an endocrine organ due to its now well-established role in the secretion of myokines. The use of the term myokine to describe cytokines and other peptides produced by muscle as signalling molecules was proposed in 2003.
Sources: en.wikipedia.org
=== 19th and early 20th centuries === Lithium was first used in the 19th century as a treatment for gout after scientists discovered that, at least in the laboratory, lithium could dissolve uric acid crystals isolated from the kidneys. The levels of lithium needed to dissolve urate in the body, however, were toxic. Because of prevalent theories linking excess uric acid to a range of disorders, including depressive and manic disorders, Carl Lange in Denmark and William Alexander Hammond in New York City used lithium to treat mania from the 1870s onwards. By the turn of the 20th century, as theory regarding mood disorders evolved and so-called "brain gout" disappeared as a medical entity, the use of lithium in psychiatry was largely abandoned; however, several lithium preparations were still produced for the control of renal calculi and uric acid diathesis. As accumulating knowledge indicated a role for excess sodium intake in hypertension and heart disease, lithium salts were prescribed to patients for use as a replacement for dietary table salt (sodium chloride). This practice and the sale of lithium itself were both banned in the United States in February 1949, following the publication of reports detailing side effects and deaths.
Among those from the world of politics to be recognised in the 2024 Birthday Honours is former prime minister Gordon Brown, who is made a Companion of Honour, and former MP Wayne David, who receives a knighthood. 16 June – Grant StClair-Armstrong, the Reform UK candidate for North West Essex, resigns from the party after historic blog posts emerge in which he urged people to vote for the British National Party. ITV Wales holds an election debate between senior figures from the three main political parties in Wales; David TC Davies (Conservative), Jo Stevens (Labour) and Liz Saville Roberts (Plaid Cymru). 17 June – Nigel Farage launches Reform UK's election manifesto, which he describes as a contract, and which chiefly proposes a freeze on non-essential immigration. Lord Cashman is suspended from the Parliamentary Labour Party for describing Rosie Duffield as "frit or lazy" in a social media post for withdrawing from hustings meetings over concerns for her safety. BBC Sounds launches an Election 2024 livestream, bringing together all the election news and programming, such as Newscast, Today, Question Time and Sunday with Laura Kuenssberg. The livestream is scheduled to run until 8 July. 18 June – LBC's Nick Ferrari presents the first of two editions of Britain's Next PM, a phone-in giving listeners the opportunity to speak to Keir Starmer and Rishi Sunak, with Starmer appearing on the first edition and Sunak the following day. The deadline for people wishing to register to vote in time for the 2024 general election expires at 23:59.
=== Medications === Oral contraceptives containing ethinylestradiol can increase SHBG levels 2- to 4-fold and decrease free testosterone concentrations by 40 to 80% in women. They can be used to treat symptoms of hyperandrogenism like acne and hirsutism. Some oral contraceptives, namely those containing high doses of ethinylestradiol (which have been discontinued and are no longer marketed), can increase SHBG levels as much as 5- to 10-fold. Some medications, such as certain anabolic steroids like mesterolone and danazol and certain progestins like levonorgestrel and norethisterone, have high affinity for SHBG and can bind to it and displace endogenous steroids from it, thereby increasing free concentrations of these endogenous steroids. It has been estimated that therapeutic levels of danazol, methyltestosterone, fluoxymesterone, levonorgestrel, and norethisterone would respectively occupy or displace from testosterone 83–97%, 48–69%, 42–64%, 16–47%, and 4–39% of SHBG binding sites, while others with low affinity for SHBG such as ethinylestradiol, cyproterone acetate, and medroxyprogesterone acetate would occupy or displace from testosterone 1% or fewer SHBG binding sites. Selective androgen receptor modulators (SARMs) also reduce SHBG.
== Oxygen-20 == Oxygen-20 has a half-life of 13.51±0.05 s and decays by β− decay to 20F. It is one of the known cluster decay ejected particles, being emitted in the decay of 228Th with a branching ratio of about (1.13±0.22)×10−13.
This is normally achieved through regular blood tests, although continuous blood sugar testing equipment (Continuous Glucose Monitors or CGMs) are now becoming available which could help to refine this balancing act once widespread usage becomes common.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.